RT Journal Article SR Electronic T1 Treatment Results of MammoSite Catheter in Combination with Whole-breast Irradiation JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 355 OP 360 VO 36 IS 1 A1 ALEXANDER GITT A1 HUGO BÖSE-RIBEIRO A1 CARSTEN NIEDER A1 PHILIPP GÜNTHER KUP A1 HORST HERMANI A1 HELMUT BÜHLER A1 HASAN YAVUZ ERGÖNENÇ A1 DOROTHEE DRÜPPEL A1 IRENÄUS ANTON ADAMIETZ A1 KHASHAYAR FAKHRIAN YR 2016 UL http://ar.iiarjournals.org/content/36/1/355.abstract AB Aim. To report the initial outcomes of patients treated with the MammoSite brachytherapy device (MSBT) as a boost followed by external whole-breast irradiation (WBI). Patients and Methods: From June 2011 to March 2014, 107 patients (typically with pT1-2, pN0-1, M0 disease) were treated with breast-conserving therapy and adjuvant radiotherapy with MSBT (15 Gy in 2.5-Gy fractions) followed by WBI (median=50.4 Gy). Toxicity was classified according to the Common Terminology Criteria for Adverse Events v3.0. The median follow-up was 21 months. Results: To date, no ipsilateral breast-tumor recurrences have been observed; 102 patients (95%) were alive at last follow-up. Two patients (2%) developed distant metastases. Five patients (5%) died during follow-up, only one as a result of breast cancer. The 2-year disease-free survival was 95±3%. The incidence of asymptomatic and symptomatic seroma in 90 days after MSBT was 28% and 10%, respectively. Infectious mastitis was observed in three patients (3%), who were treated successfully with antibiotics. Only three patients (3%) developed RT-induced dermatitis greater than grade 2 after WBI. Conclusion: The boost technique used in this study seems to provide excellent local control with acceptable toxicity, similar to the results observed with other forms of interstitial accelerated partial-breast irradiation as a boost. Long-term follow-up is necessary to refine the patient selection criteria and to assess efficacy and late toxicities.